<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545087</url>
  </required_header>
  <id_info>
    <org_study_id>16007</org_study_id>
    <secondary_id>I8D-MC-AZEN</secondary_id>
    <nct_id>NCT03545087</nct_id>
  </id_info>
  <brief_title>A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants</brief_title>
  <official_title>Pharmacokinetics of Lanabecestat (LY3314814) in Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether lanabecestat can be safely prescribed in
      participants with kidney impairment without a dose adjustment.

      Participants will be on study for up to 6 weeks; this includes a 2-week screening and a
      follow-up about 10 days after final drug administration.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Stopped for futility. Phase 3 studies not likely to meet primary endpoints.
  </why_stopped>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under The Concentration Versus Time Curve From Zero To Infinity (AUC[0-∞]) for Lanabecestat</measure>
    <time_frame>Baseline through 168 hours after the administration of study drug</time_frame>
    <description>PK: AUC(0-∞) for Lanabecestat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of Lanabecestat</measure>
    <time_frame>Baseline through 168 hours after the administration of study drug</time_frame>
    <description>PK: Cmax of Lanabecestat</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Lanabecestat Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanabecestat administered orally to participants with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanabecestat Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanabecestat administered orally to participants with severe renal impairment, not on dialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanabecestat</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lanabecestat Control</arm_group_label>
    <arm_group_label>Lanabecestat Severe Renal Impairment</arm_group_label>
    <other_name>LY3314814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.</description>
    <arm_group_label>Lanabecestat Severe Renal Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Have a body mass index (BMI) of 19 to 40 kilograms per meter square (kg/m²)

        Exclusion Criteria:

          -  Have a history of or current significant ophthalmic disease, particularly any eye
             problem involving the retina

          -  Have moderate or severe vitiligo or any other clinically significant disorder of skin
             or hair pigmentation

          -  Have acute unstable neuropsychiatric disease

          -  Have active or uncontrolled neurologic disease, or clinically significant head injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Ctr.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

